Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

RenSuper Biologics: Empowering Next-Generation Dual Payload ADCs With AI Driven Precision & Scalability

By | 8 June 2026

Leveraging RenLite common light chain to eliminate mismatching, ensuring high homogeneity and “antibody like” stability for complex dual payload formats
Combining two distinct, complementary MoAs on a single molecule to tackle tumor heterogeneity and bypass resistance
The RenSuper Workstation AI Platform scans 200+ TAA targets and hundreds of thousands of ready-to go antibodies to match the ideal lead with optimal internalization in record time